Paradigm Biopharmaceuticals completes $35 million capital raising
The company aims to develop and commercialise its safe and effective treatment for sufferers of osteoarthritis.
Company
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application. Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).
175 stories · page 5 of 9
Paradigm Biopharmaceuticals confirms knee osteoarthritis pain reduction ahead of phase 3 clinical trial of Zilosul
Zilosul was successful in reducing knee osteoarthritis pain score by 45%.
Paradigm Biopharmaceuticals in halt pending response to Food & Drug Administration update
The halt will remain in place until Monday, April 6, or until an announcement is released to the market.
Paradigm Biopharmaceuticals commences Zilosul® treatment for expanded access program
10 Patients are being treated for knee osteoarthritis using the trademarked injectable pentosan polysulphate sodium drug Zilosul®.
Panoramic Resources ready for Barminco to take over mining at Savannah
The company also noted that first stoped ore from the Savannah North deposit is on schedule for March 2020.
Paradigm Biopharmaceuticals meets with US Food and Drug Administration to discuss development of flagship drug Zilosul®
The biotechnology company is undergoing regulatory processes in Australia, the US and Europe for its injectable Pentosan Polysulfate Sodium (iPPS) drug.
Paradigm Biopharmaceuticals treats first US patient with Zilosul®
Paradigm will treat 10 patients in the US comprised of ex-NFL players with its development drug Zilosul®.
Paradigm Biopharmaceuticals presents patient-centric research at World MPS Symposium
The company is focused on repurposing the injectable drug pentosan polysulphate sodium to treat inflammation in MPS VI patients.
Paradigm Biopharmaceuticals provides market update
Paradigm will be meeting with the US FDA in Feb 2020 for a pre-IND meeting among other things.
Paradigm Biopharmaceuticals’ board member buys $300,000 worth of shares
Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.
Paradigm Biopharmaceuticals’ Paul Rennie adds over $500,000 stock to holding
Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.
Paradigm Biopharmaceuticals targets 2019-20 milestones for OA-MPS-BMEL pipeline
The biotech gained up to 5% by lunch on confirming FY20 milestones, including an early-2020 filing with the US FDA for an OA drug.
Paradigm Biopharmaceuticals shares get a boost following IRB approval to treat ex NFL players
The IRB has followed the FDA in approving the submission to treat 10 ex NFL players with Paradigm’s trial drug Zilosul.
Paradigm Biopharmaceuticals journal publication confirms discovery, shares surge
The company’s data has been published in the peer-reviewed international scientific journal PLoS One
Paradigm Biopharmaceuticals gets FDA clearance for investigational new drug application
FDA Clearance means validation of Paradigm’s safety data, the finished product’s quality and confirmation of an unmet medical need.
Paradigm Biopharmaceuticals makes new breakthrough for iPPS, shares rise
New clinical trial data shows that its trial drug Zilosul (iPPS) also reduces knee cartilage degradation.
Paradigm Biopharmaceuticals files Investigational New Drug submission for ZilosulÒ with FDA
ZilosulÒ (iPPS) is a potential first-line therapeutic treatment for osteoarthritis and other diseases affecting the musculoskeletal system.
Paradigm Biopharmaceuticals director acquires 140,000 shares valued at almost $170,000
Non-executive director Chris Fullerton participated in a $26.3 million entitlement offer and has also purchased shares on-market.
Paradigm Biopharmaceuticals CEO shows faith in company with $49,000 on-market purchase
To facilitate its ongoing development and growth, the company signed employment agreements with five new staff members in late June.
Paradigm Biopharmaceuticals Ltd fully funded as it advances iPPS development
The company is focused on creating commercial opportunities that will generate potential revenue from early sales of finished product or through partnering/commercial transactions.